Late-Course Accelerated Hyperfractionated IMRT for Locoregionally Advanced Nasopharyngeal Carcinoma
Launched by GUANGXI MEDICAL UNIVERSITY · Oct 22, 2008
Trial Information
Current as of May 28, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Histologically proven non-keratinizing or undifferentiated type nasopharyngeal carcinoma for primary treatment with curative intent
- • According to AJCC 2002 Staging System, clinical stage must be Ⅱb-Ⅳb
- • Age between 18-70
- • Karnofsky performance status ≥70
- • WBC ≥4,000/mm3, PLT ≥ 100,000/mm3,serum creatinine ≤ 1.6 mg/dl
- • Without radiotherapy or chemotherapy
- • Signed study-specific consent form prior to study entry
- Exclusion Criteria:
- • Patients with distant metastasis
- • Pregnant or lactating women
- • The presence of uncontrolled life-threatening illness
- • Patients who received radiotherapy or chemotherapy previously
About Guangxi Medical University
Guangxi Medical University is a prominent educational and research institution located in Nanning, China, dedicated to advancing healthcare through innovative clinical research and medical education. As a clinical trial sponsor, the university leverages its extensive expertise in medical sciences to conduct rigorous research aimed at improving patient outcomes and contributing to the global understanding of various health conditions. With a commitment to ethical standards and scientific integrity, Guangxi Medical University collaborates with healthcare professionals and institutions to facilitate the development of new therapies and interventions, ultimately enhancing the quality of care within the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nanning, Guangxi, China
Patients applied
Trial Officials
Heming Lu, MD
Study Chair
Department of Radiation Oncology, People's Hospital of Guangxi Zhuang Autonomous Region
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials